$DFTX

Definium Therapeutics, Inc.

Definium Therapeutics is a clinical-stage biopharmaceutical company developing product candidates for brain health disorders. Its lead candidates are DT120 ODT, a proprietary form of lysergide D-tartrate being developed for adults with generalized anxiety disorder and major depressive disorder, and DT402, a proprietary form of R(-)-MDMA being developed for adults with autism spectrum disorder. The company also explores other drug-development programs, including with external collaborators. Definium is advancing DT120 ODT through Phase 3 trials for generalized anxiety disorder and major depressive disorder, and DT402 through a Phase 2a trial for autism spectrum disorder. It currently earns no product sales from approved medicines; its stated activities focus on research and development, with plans to commercialize candidates if they receive regulatory approval. It sources clinical and non-clinical drug supplies from third-party manufacturers. Definium is headquartered in New York, NY.

No enriched coverage for $DFTX in the last 7 days.

No SEC Form 4 filings for $DFTX in the last 30 days.

See all $DFTX insider activity →

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

DFTX sentiment & insider activity

Recent DFTX coverage spans financial news, earnings and corporate actions.

What's driving DFTX

  • JP Morgan kept its Overweight rating on Definium Therapeutics and increased its price target to $85 from $84, suggesting a 181.8% upside from the Nov 16 close of $30.16.

    tradingview.com · Nov 17, 2026

  • Positive trial data and a pending FDA filing are likely to lift DFTX shares as investors price in potential approval.

    finance.yahoo.com · Nov 11, 2026

  • RBC Capital reaffirmed its Outperform rating for Definium Therapeutics and increased its price target to $70 from $66, suggesting a 97.8% upside from the Nov 9 close of $35.39.

    tradingview.com · Nov 10, 2026

  • Positive trial data and regulatory designation are likely to boost investor sentiment.

    tradingview.com · Nov 9, 2026

  • Positive trial data and regulatory designation are likely to drive buying pressure on DFTX.

    SEC EDGAR 8-K · Nov 9, 2026

AlphAI scores every news story that mentions DFTX with an AI model for sentiment and relevance, and aggregates insider trades from Definium Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DFTX

Score

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXHighEarnings

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

Definium Therapeutics (DFTX) will present positive topline data from three Phase 3 studies of DT120 ODT for generalized anxiety disorder (GAD) and major depressive disorder (MDD) at the 2026 NEI Fall Congress. The studies, Panorama, Emerge, and Voyage, showed efficacy and safety, with DT120 ODT receiving FDA Breakthrough Therapy designation for GAD and MDD. The presentations will include comprehensive safety data and support continued clinical assessment.

Related tickers